stockportfolio.pro
Kenvue Inc. (KVUE)
Consumer Defensive · Household & Personal Products · NYSE
Kenvue Inc. revenue & earnings — last 5 fiscal years
| Metric | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $15.05B | $14.95B | $15.44B | $15.46B | $15.12B |
| Gross profit | $8.42B | $8.29B | $8.64B | $8.96B | $8.79B |
| Net income | $2.08B | $2.09B | $1.66B | $1.03B | $1.47B |
| Net margin | 13.8% | 14.0% | 10.8% | 6.7% | 9.7% |
Source: Kenvue Inc. SEC filings (10-K).
What growth is priced into KVUE stock?
At today's market cap of $34.41B, Kenvue Inc. is priced for free-cash-flow growth of about 7.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.72B from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 5 years of Kenvue Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track KVUE in your portfolio →
Kenvue Inc. financial history by metric
About Kenvue Inc.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Kenvue Inc. — frequently asked questions
What is Kenvue Inc.'s revenue?
Kenvue Inc. (KVUE) reported revenue of $15.12B for fiscal year 2025, down 2.1% from the prior year, according to its SEC filings.
Is Kenvue Inc. profitable?
Yes. KVUE earned net income of $1.47B in fiscal 2025, a net margin of 9.7%.
What is KVUE's P/E ratio?
Kenvue Inc. trades at a price-to-earnings ratio of about 20.8 based on the latest data in our nightly-refreshed cache.
How fast is Kenvue Inc. growing?
KVUE's revenue grew at roughly 0.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Kenvue Inc. have?
As of fiscal year 2025, KVUE carried roughly $1.45B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Kenvue Inc.'s gross margin?
KVUE's gross margin was 58.1% in fiscal 2025 — gross profit of $8.79B on revenue of $15.12B.
What is Kenvue Inc.'s market cap?
Kenvue Inc. (KVUE) has a market capitalization of about $34.41B, based on the latest data in our nightly-refreshed cache.
When does Kenvue Inc.'s fiscal year end?
KVUE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into KVUE stock?
At today's market cap of $34.41B, Kenvue Inc. is priced for free-cash-flow growth of about 7.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.72B from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from Kenvue Inc.'s official SEC filings (10-K and 10-Q), covering 5 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.